The pill of recovery; Molnupiravir for treatment of COVID-19 patients; a systematic review.

ABSTRACT:

Background

Throughout the time of the global pandemic of SARS-CoV-2 virus, there has been a compelling necessity for the development of effective antiviral agents and prophylactic vaccines to limit the virus spread, disease burden, hospitalization, and mortality. Until mid of 2021, the NIH treatment guideline declared no single oral therapy was proven to treat mild to moderate cases. A new hope arose when a repurposed direct acting oral anti-viral agent "Molnupiravir" was shown to be effective in decreasing mortality and need for hospitalization in mild to moderate cases with relatively good safety profile; exhibiting a significant reduction in virus titers only after two days from administration. Molnupiravir recently granted the FDA emergency use authorization to treat mild to mo

SUBMITTER: Kamal L 

PROVIDER: S-EPMC8906919 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature